Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium

被引:27
作者
Baden, Tatsuya [1 ]
Yamawaki, Hideyuki [1 ]
Saito, Kazuaki [1 ]
Mukohda, Masashi [1 ]
Okada, Muneyoshi [1 ]
Hara, Yukio [1 ]
机构
[1] Kitasato Univ, Sch Vet Med, Dept Vet Pharmacol, Aomori 0348628, Japan
关键词
endothelial cell; glucose metabolite; apoptosis; angiotensin receptor blocker; diabetes;
D O I
10.1016/j.bbrc.2008.06.023
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Methylglyoxal (MGO) is a metabolite of glucose. Since serum MGO level is increased in diabetic patients, MGO is implicated in diabetic complications related to vascular injury. We have recently demonstrated that glucose metabolite is a more powerful stimulant for endothelial cells (ECs) injury rather than glucose or advanced glycation-end products. Recent clinical trials suggest that angiotensin receptor blockers are effective to prevent diabetes-associated cardiovascular disorders beyond blood pressure lowering effect. To explore the mechanisms, we examined effects of telmisartan on MGO-induced ECs injury. Treatment of human umbilical vein ECs with MGO (560 mu M) induced time-dependent (0-24 h) cell death. MGO-induced cell death was apoptosis since MGO increased cleaved caspase-3 expression. Telmisartan (0.1-10 mu M) inhibited MGO-induced cell death and caspase-3 activation. These results indicate that telmisartan prevents MGO-induced apoptosis by inhibiting caspase-3 activation, which might explain at least in part the beneficial effects of telimisartan against diabetes-related cardiovascular diseases. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:253 / 257
页数:5
相关论文
共 33 条
[11]   Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-γ-modulating activity, on nitric oxide bioavailability and atherosclerotic change [J].
Ikejima, Hideyuki ;
Imanishi, Toshio ;
Tsujioka, Hiroto ;
Kuroi, Akio ;
Kobayashi, Katsunobu ;
Shiomi, Masashi ;
Muragaki, Yasuteru ;
Mochizuki, Seiichi ;
Goto, Masami ;
Yoshida, Kiyoshi ;
Akasaka, Takashi .
JOURNAL OF HYPERTENSION, 2008, 26 (05) :964-972
[12]   Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ [J].
Imayama, Ikuyo ;
Ichiki, Toshihiro ;
Inanaga, Keita ;
Ohtsubo, Hideki ;
Fukuyama, Kae ;
Ono, Hiroki ;
Hashiguchi, Yasuko ;
Sunagawa, Kenji .
CARDIOVASCULAR RESEARCH, 2006, 72 (01) :184-190
[13]   Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes [J].
Kilhovd, BK ;
Giardino, I ;
Torjesen, PA ;
Birkeland, KI ;
Berg, TJ ;
Thornalley, PJ ;
Brownlee, M ;
Hanssen, KF .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (02) :163-167
[14]   Methylglyoxal induces apoptosis mediated by reactive oxygen species in bovine retinal pericytes [J].
Kim, J ;
Son, JW ;
Lee, JA ;
Oh, YS ;
Shinn, SH .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (01) :95-100
[15]   Glyoxal and methylglyoxal levels in diabetic patients: Quantitative determination by a new GC/MS method [J].
Lapolla, A ;
Flamini, R ;
Vedova, AD ;
Senesi, A ;
Reitano, R ;
Fedele, D ;
Basso, E ;
Seraglia, R ;
Traldi, P .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (09) :1166-1173
[16]   Proapoptotic effects of ANG II in human coronary artery endothelial cells:: role of AT1 receptor and PKC activation [J].
Li, DY ;
Yang, BC ;
Philips, MI ;
Mehta, JL .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (03) :H786-H792
[17]  
Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]
[18]   Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Lindholm, LH ;
Ibsen, H ;
Dahlöf, B ;
Devereux, RB ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Julius, S ;
Kjeldsen, SE ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H ;
Aurup, P ;
Edelman, J ;
Snapinn, S .
LANCET, 2002, 359 (9311) :1004-1010
[19]  
MONCADA S, 1991, PHARMACOL REV, V43, P109
[20]   Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes [J].
Mostafa, Ahmed A. ;
Randell, Edward W. ;
Vasdev, Sudesh C. ;
Gill, Vicki D. ;
Han, Yingchun ;
Gadag, Vereesh ;
Raouf, Ahmed A. ;
El Said, Hala .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2007, 302 (1-2) :35-42